Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Haniza Omar"'
Autor:
Muhammad Radzi Abu Hassan, Rosaida Hj Md Said, Zalwani Zainuddin, Haniza Omar, Siti Maisarah Md Ali, Siti Aishah Aris, Huan-Keat Chan
Publikováno v:
Heliyon, Vol 9, Iss 6, Pp e16652- (2023)
Background and purpose: and purpose: Non-alcoholic fatty liver disease (NAFLD) is a significant global health concern with limited pharmacotherapy options. This study aimed to evaluate the effectiveness of a standardized extract of Phyllanthus niruri
Externí odkaz:
https://doaj.org/article/e57ab0b059bf4605b35f514f20dc9845
Publikováno v:
Case Reports in Clinical Medicine. 11:116-121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d428fee3a548ac95caf14b3e4b92aa8
https://doi.org/10.4236/crcm.2022.114018
https://doi.org/10.4236/crcm.2022.114018
Autor:
Sasikala Siva, Anchalee Avihingsanon, Nicole Ngo-Giang-Huong, Hoi-Poh Tee, Suparat Khemnark, Alistair Swanson, Isabelle Andrieux-Meyer, François Simon, Haniza Omar, Kanawee Thetket, Shahnaz Murad, Sombat Thanprasertsuk, Sabine Yerly, Caroline Menetrey, Vishal Goyal, Bernard Pécoul, Satawat Thongsawat, Muhammad Radzi Abu Hassan, Francois Bompart, Wah-Kheong Chan, Suresh Kumar, Soek-Siam Tan, Tim R. Cressey, Nicolas Salvadori, Hajjah Rosaida Hj Mohd Said
Publikováno v:
The Lancet Gastroenterology & Hepatology. 6:448-458
In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13bbe1c771fa602f9f313d99aac7d224
https://doi.org/10.1016/s2468-1253(21)00031-5
https://doi.org/10.1016/s2468-1253(21)00031-5
Autor:
Norleen Mohamed Ali, Haniza Omar, Huan-Keat Chan, Noor Aliza Mutalib, Hin-Seng Wong, Fei Yee Lee, Muhammad Radzi Abu Hassan
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:1669-1679
PURPOSE To determine the incidence, demographic profile, background of reporters, causative agents, severity and clinical outcomes of hepatic adverse drug reaction (ADR) reports in Malaysia using the national ADR reporting database. METHODS The ADR r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd583c920a512fdd6a8915be739c7d1
https://doi.org/10.1002/pds.5153
https://doi.org/10.1002/pds.5153
Publikováno v:
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
Background and Aim The advent of endoscopic ultrasound‐guided biliary drainage (EUS‐BD) has provided an inimitable alternative for gaining biliary access in patients who fail conventional endoscopic drainage. The antimigratory features of the par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1cdb1a4d45298d3150e1066a67b1c4
http://europepmc.org/articles/PMC7731807
http://europepmc.org/articles/PMC7731807
Autor:
Jessica Markby, Sonjelle Shilton, Xiaohui Sem, Huan Keat Chan, Rosaida Md Said, Sasikala Siva, Zalwani Zainuddin, Norasiah Abu Bakar, Haniza Omar, Ryan Jose III Ruiz, Mary Gaeddert, Alexander Tyshkovskiy, Madeline Adee, Jagpreet Chhatwal, Suresh Kumar, Jean-Michel Piedagnel, Rozainanee Mohd Zain, Caroline Menétrey, Fazidah Yuswan, Nazrila Hairizan Nasir, Isabelle Andrieux-Meyer, Fatanah Ismail, Rozita Zakaria, Ruziaton Hasim, Shahnaz Murad, Philippa Easterbrook, Muhammad Radzi Abu Hassan
Publikováno v:
BMJ Open
IntroductionTo achieve the elimination of hepatitis C virus (HCV), substantial scale-up in access to testing and treatment is needed. This will require innovation and simplification of the care pathway, through decentralisation of testing and treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3f78118e65849685663b8003d4bf58
http://europepmc.org/articles/PMC8713014
http://europepmc.org/articles/PMC8713014
Autor:
Keat, CHAN Huan, Azmi, HASSALI Muhamed, MD SAID Rosaida, Haniza, OMAR, Aliza, ABD MUTALIB Noor, Walter, DE ROZARIO Frederick, Radzi, ABU HASSAN Muhammad
Introduction Malaysia has been actively battling hepatitis C since 2016, primarily through partnerships with access-oriented nonprofit organizations and drug price control by compulsory licensing of sofosbuvir, a patented direct-acting antiviral. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd52a680b98cc862826a79d21c835f3d
Autor:
Mohamed Azmi Hassali, Haniza Omar, Noor Aliza Abd Mutalib, Rosaida Md Said, Frederick Walter De Rozario, Huan-Keat Chan, Muhammad Radzi Abu Hassan
Publikováno v:
Hepatitis Monthly. 21
Background: Malaysia has been fully committed to the global endeavor to eliminate hepatitis C virus (HCV) infection by 2030. In early 2018, the Ministry of Health (MOH) embarked on a “one-size-fits-all strategy” by introducing generic versions of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8ed240b79d675cca31cff5238bb2fc8
https://doi.org/10.5812/hepatmon.113226
https://doi.org/10.5812/hepatmon.113226
Autor:
Chai-Zhen Hoo, Kar-Choon Tan, Salmi Abdullah, Benedict Lim-Heng Sim, Haniza Omar, Soek-Siam Tan
Publikováno v:
ACG Case Reports Journal. 9:e00760
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e7ec2628bdbfd6d00c276d26b96df
https://doi.org/10.14309/crj.0000000000000760
https://doi.org/10.14309/crj.0000000000000760
Autor:
Nicole Ngo-Giang-Huong, Bernard Pecould, François Simon, Nicolas Salvadori, Suparat Khemnark, Alistair Swanson, Hoi-Poh Tee, Suresh Kumar, Tim R. Cressey, Sasikala Siva, Vishal Goyal, Sombat Thanprasertsuk, Anchalee Avihingsanon, Isabelle Andrieux-Meyer, Haniza Omar, Caroline Menetrey, Sabine Yerly, Muhammad Radzi Abu Hassan, Francois Bompart, Wah-Kheong Chan, Kanawee Thetket, Shahnaz Murad, Satawat Thongsawat, S. G. Tan, Hajjah Rosaida Hj Mohd Said
Publikováno v:
SSRN Electronic Journal.
Background: In low- and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic NS5A inhibitor, and sofosbuvir has shown efficacy and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e444fd9c593c2248a23b23952b773b74
https://doi.org/10.2139/ssrn.3745205
https://doi.org/10.2139/ssrn.3745205